INVO BIOSCIENCE INC (INVO)
US44984F4019 - Common Stock
Taking everything into account, INVO scores 2 out of 10 in our fundamental rating. INVO was compared to 192 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of INVO have multiple concerns. INVO is valued quite expensively, but it does show have an excellent growth rating.
1. Profitability
1.1 Basic Checks
INVO had negative earnings in the past year.
In the past year INVO has reported a negative cash flow from operations.
INVO had negative earnings in each of the past 5 years.
INVO had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
With a Return On Assets value of -38.47%, INVO is not doing good in the industry: 60.94% of the companies in the same industry are doing better.
INVO has a worse Return On Equity (-899.92%) than 89.06% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -38.47% | ||
| ROE | -899.92% | ||
| ROIC | N/A |
ROA(3y)-122.53%
ROA(5y)-112.88%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Gross Margin of INVO (41.20%) is worse than 63.54% of its industry peers.
INVO's Gross Margin has declined in the last couple of years.
INVO does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 41.2% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-26.71%
GM growth 5Y-15.12%
2. Health
2.1 Basic Checks
INVO does not have a ROIC to compare to the WACC, probably because it is not profitable.
INVO has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, INVO has more shares outstanding
INVO has a better debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of -5.12, we must say that INVO is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -5.12, INVO is doing worse than 72.40% of the companies in the same industry.
INVO has a Debt/Equity ratio of 2.39. This is a high value indicating a heavy dependency on external financing.
The Debt to Equity ratio of INVO (2.39) is worse than 87.50% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.39 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -5.12 |
ROIC/WACCN/A
WACC7.98%
2.3 Liquidity
A Current Ratio of 0.15 indicates that INVO may have some problems paying its short term obligations.
Looking at the Current ratio, with a value of 0.15, INVO is doing worse than 98.44% of the companies in the same industry.
A Quick Ratio of 0.12 indicates that INVO may have some problems paying its short term obligations.
With a Quick ratio value of 0.12, INVO is not doing good in the industry: 98.44% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.15 | ||
| Quick Ratio | 0.12 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 49.06% over the past year.
INVO shows a strong growth in Revenue. In the last year, the Revenue has grown by 264.07%.
Measured over the past years, INVO shows a very strong growth in Revenue. The Revenue has been growing by 43.87% on average per year.
EPS 1Y (TTM)49.06%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q72%
Revenue 1Y (TTM)264.07%
Revenue growth 3Y42.68%
Revenue growth 5Y43.87%
Revenue growth Q2Q393.48%
3.2 Future
The Earnings Per Share is expected to grow by 41.42% on average over the next years. This is a very strong growth
Based on estimates for the next years, INVO will show a very strong growth in Revenue. The Revenue will grow by 101.26% on average per year.
EPS Next Y50%
EPS Next 2Y41.42%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year199.65%
Revenue Next 2Y172.81%
Revenue Next 3Y152.43%
Revenue Next 5Y101.26%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
INVO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year INVO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as INVO's earnings are expected to grow with 41.42% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.42%
EPS Next 3YN/A
5. Dividend
5.1 Amount
INVO does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
INVO BIOSCIENCE INC
NASDAQ:INVO (4/29/2024, 7:07:16 PM)
After market: 1.03 -0.03 (-2.83%)1.06
+0.08 (+8.16%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap2.78M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -38.47% | ||
| ROE | -899.92% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 41.2% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.14
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.39 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 0.15 | ||
| Quick Ratio | 0.12 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)49.06%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y50%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)264.07%
Revenue growth 3Y42.68%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y